After IPO, BioNTech nabs cell therapy startup Neon Therapeutics

There’s been a deal at the annual J.P. Morgan Healthcare Conference in San Francisco, but probably not with the largest names and certainly not big bucks.

The acquirer is Germany’s BioNTech, which has gotten off some monster raises and a middling $150 million IPO late last year and is paying just $67 million in an all-stock deal (around double its market cap as of yesterday, but much less than its IPO) to snap up Neon Therapeutics and its early-stage T-cell work.